FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

27 letters match. Newest first.

  1. Thomas Brunner Hygiene GmbH

    Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.

    High risk
  2. Lexia LLC

    FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.

    High risk
  3. Miers Laboratories, Ltd

    FDA warns Miers Laboratories over manufacturing violations and places import alert on its drugs.

    High risk
  4. Kath Khemicals LLC

    FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.

    High risk
  5. Vidaslim Co.

    Vidaslim Co. dietary supplements are adulterated by CGMP failures and misbranded by label violations.

    Medium
  6. Kenil Healthcare Private Limited

    FDA warns Kenil Healthcare over adulterated drugs from India due to cleaning, packaging, and quality failures.

    High risk
  7. Anti L’Age

    FDA warned Anti L'Age over dietary supplements made without required manufacturing standards, records, quality controls, and proper labeling.

    Medium
  8. Mother Earth Minerals, Inc.

    FDA warns Mother Earth Minerals that its Calcium, Magnesium and Silver are unapproved drugs with disease claims and lack quality controls.

    High risk
  9. Yiling Pharmaceutical Ltd.

    FDA warns Yiling Pharmaceutical over manufacturing violations causing cross-contamination risks in finished drugs from shared equipment.

    High risk
  10. BEO Pharma Inc. dba BEO Pharmaceuticals Inc.

    FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.

    High risk
  11. Micro Orgo Chem

    Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.

    High risk
  12. Little Moon Essentials, LLC

    FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.

    High risk
  13. Regenerative Processing Plant, LLC

    FDA warns Regenerative Processing Plant over unapproved, misbranded Regener-Eyes eye drops and serious sterile manufacturing violations.

    High risk
  14. Intercos Europe S.p.A

    FDA warned Intercos Europe S.p.A over current good manufacturing practice violations in OTC sunscreen drugs, including missing glycerin DEG/EG testing and poor investigations.

    High risk
  15. Txsyn Int. LLC

    FDA says Txsyn Int. repackaged dietary supplements without required manufacturing procedures and quality approval.

    Medium
  16. Omega Tech Labs LLC

    Omega Tech Labs in Boise, Idaho, released microbially contaminated combination drug-device product and failed manufacturing rules.

    High risk
  17. Curtis Jacquot dba Pacific BioLogic Co.

    Pacific BioLogic's dietary supplements had manufacturing violations and disease claims making them unapproved drugs.

    High risk
  18. Accra-Pac, Inc. dba Voyant Beauty

    Voyant Beauty's Elkhart, Indiana plant made OTC aerosol drugs contaminated with benzene and failed to investigate or test properly.

    High risk
  19. B & J Group

    B & J Group, a Morrisville, PA contract filler of OTC hand sanitizer, was cited by FDA for skipping finished-product and ingredient testing.

    High risk
  20. Ultra Chem Labs Corporation

    FDA warns Ultra Chem Labs about methanol-tainted hand sanitizer sold as an unapproved, misbranded drug.

    High risk
  21. Urban Electric Power

    Urban Electric Power hand sanitizers contained unacceptable acetaldehyde and acetal impurities and had CGMP violations.

    High risk
  22. Eksa Mills S.A. de C.V.

    FDA cited Eksa Mills for CGMP violations, including shared-equipment contamination risks, after an April 2022 inspection of its Mexican drug facility.

    High risk
  23. Muscle Feast, LLC

    Muscle Feast, LLC lacked ingredient identity and finished-product specifications for dietary supplements, FDA says.

    Medium
  24. Cetylite Industries, Inc.

    FDA warned Cetylite Industries over CGMP violations at its Pennsauken, NJ facility, including unvalidated testing and inadequate OOS investigations for topical anesthetics.

    High risk
  25. Indiana Chem-Port

    Indiana Chem-Port API manufacturer cited for CGMP deviations including dirty equipment, unvalidated processes, and cleaning failures.

    High risk
  26. Gulsah Uretim Kozmetik Sanayi Anonim Sirketi

    Turkish OTC drug maker Gulsah failed to test its products and ingredients, and FDA blocked its U.S. imports.

    High risk
  27. Novel Laboratories, Inc. d.b.a LUPIN

    FDA warned Lupin's Novel Laboratories over manufacturing violations including equipment cross-contamination and unvalidated temazepam capsules.

    High risk